Korro Bio, Inc. (KRRO) - Total Assets
Based on the latest financial reports, Korro Bio, Inc. (KRRO) holds total assets worth $183.62 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Korro Bio, Inc. (KRRO) cash conversion ratio for how efficiently the company converts equity into cash flow.
Korro Bio, Inc. - Total Assets Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s total assets have evolved over time, based on quarterly financial data. See Korro Bio, Inc. stock price for real-time trading data and today's change.
Korro Bio, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Korro Bio, Inc.'s total assets of $183.62 Million consist of 72.6% current assets and 27.4% non-current assets. Explore Korro Bio, Inc. working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.2% |
| Accounts Receivable | $969.00K | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Korro Bio, Inc.'s current assets represent 72.6% of total assets in 2025, a decrease from 90.7% in 2017.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2025, down from 90.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
Korro Bio, Inc. Competitors by Total Assets
Key competitors of Korro Bio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Seegene Inc
KQ:096530
|
Korea | ₩1.27 Trillion |
Korro Bio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.13 | 9.41 | 19.09 |
| Quick Ratio | 8.13 | 9.41 | 19.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $105.38 Million | $108.35 Million | $163.33 Million |
Korro Bio, Inc. - Advanced Valuation Insights
This section examines the relationship between Korro Bio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.45 |
| Latest Market Cap to Assets Ratio | 1.29 |
| Asset Growth Rate (YoY) | -49.8% |
| Total Assets | $113.51 Million |
| Market Capitalization | $146.53 Million USD |
Valuation Analysis
Above Book Valuation: The market values Korro Bio, Inc.'s assets above their book value (1.29x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Korro Bio, Inc.'s assets decreased by 49.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Korro Bio, Inc. (2017–2025)
The table below shows the annual total assets of Korro Bio, Inc. from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $113.51 Million | -49.83% |
| 2024-12-31 | $226.24 Million | +2.06% |
| 2023-12-31 | $221.66 Million | +200.59% |
| 2022-12-31 | $73.74 Million | -60.22% |
| 2021-12-31 | $185.36 Million | -29.98% |
| 2020-12-31 | $264.72 Million | +18.59% |
| 2019-12-31 | $223.22 Million | +401.07% |
| 2018-12-31 | $44.55 Million | +125.14% |
| 2017-12-31 | $19.79 Million | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more